Takeda Pharmaceutical Co ADR (NYSE: TAK) has a higher price-to-earnings ratio of 40.30x compared to its average ratio, The 36-month beta value for TAK is at 0.58. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TAK is 3.14B, and currently, shorts hold a 0.21% of that float. The average trading volume for TAK on June 25, 2024 was 1.62M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TAK) stock’s latest price update
Takeda Pharmaceutical Co ADR (NYSE: TAK) has seen a rise in its stock price by 0.19 in relation to its previous close of 12.88. However, the company has experienced a -2.01% decline in its stock price over the last five trading sessions. businesswire.com reported 2024-06-24 that OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1 “We are pleased by the approval.
TAK’s Market Performance
Takeda Pharmaceutical Co ADR (TAK) has experienced a -2.01% fall in stock performance for the past week, with a -0.88% drop in the past month, and a -8.80% drop in the past quarter. The volatility ratio for the week is 1.10%, and the volatility levels for the past 30 days are at 1.02% for TAK. The simple moving average for the past 20 days is -1.91% for TAK’s stock, with a -8.90% simple moving average for the past 200 days.
Analysts’ Opinion of TAK
Many brokerage firms have already submitted their reports for TAK stocks, with BofA Securities repeating the rating for TAK by listing it as a “Buy.” The predicted price for TAK in the upcoming period, according to BofA Securities is $20 based on the research report published on March 16, 2023 of the previous year 2023.
Cowen, on the other hand, stated in their research note that they expect to see TAK reach a price target of $24, previously predicting the price at $21. The rating they have provided for TAK stocks is “Outperform” according to the report published on July 19th, 2022.
TAK Trading at -2.23% from the 50-Day Moving Average
After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.26% of loss for the given period.
Volatility was left at 1.02%, however, over the last 30 days, the volatility rate increased by 1.10%, as shares sank -1.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.40% lower at present.
During the last 5 trading sessions, TAK fell by -1.94%, which changed the moving average for the period of 200-days by -15.59% in comparison to the 20-day moving average, which settled at $13.15. In addition, Takeda Pharmaceutical Co ADR saw -9.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TAK starting from TAKEDA PHARMACEUTICAL CO LTD, who sale 3,703,703 shares at the price of $8.10 back on Jan 24 ’24. After this action, TAKEDA PHARMACEUTICAL CO LTD now owns 3,755,583 shares of Takeda Pharmaceutical Co ADR, valued at $29,999,994 using the latest closing price.
Stock Fundamentals for TAK
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.62 for the gross margin
The net margin for Takeda Pharmaceutical Co ADR stands at 0.03. The total capital return value is set at 0.02. Equity return is now at value 2.11, with 0.99 for asset returns.
Based on Takeda Pharmaceutical Co ADR (TAK), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.15. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is 1.02.
Currently, EBITDA for the company is 1.13 trillion with net debt to EBITDA at 4.14. When we switch over and look at the enterprise to sales, we see a ratio of 2.55. The receivables turnover for the company is 6.11for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.11.
Conclusion
In conclusion, Takeda Pharmaceutical Co ADR (TAK) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
